Flavokawain A ameliorates pulmonary fibrosis by inhibiting the TGF- β signaling pathway and CXCL12/CXCR4 axis

In conclusion, our study showed that FKA inhibited CXCL12/CXCR4 signaling by inhibiting CXCL12 dimerization, blocked the CXCL12/CXCR4 signaling pathway and inhibited the TGF-β1-mediated signaling pathway to ameliorate pulmonary fibrosis, and FKA is a promising therapeutic agent for pulmonary fibrosis.PMID:37579968 | DOI:10.1016/j.ejphar.2023.175981

Source: European Journal of Pharmacology - August 14, 2023 Category: Drugs & Pharmacology Authors: Ting Xiao Dandi Gao Xiaoting Gu Yanping Zhang Yuxin Zhu Zihui Zhang Yiming He Luqing Wei Hongli Li Honggang Zhou Cheng Yang Source Type: research